More Updates from SABCS 2010

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO

EC Approves Nivolumab/Ipilimumab in Frontline Unresectable HCC

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Tim Cortese

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

The CheckMate 9DW trial found that nivolumab and ipilimumab elicited a median OS of 23.7 months compared with 20.6 months from lenvatinib or sorafenib.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD

March 5th 2025

Celebrating Women in Oncology Through Their Impactful Research and Insights

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Ariana Pelosci

Continuous Second-Line Immunotherapy May Benefit Pretreated Lung Cancer

For International Women's Day, CancerNetwork highlights impactful oncology research on topics from rising health care costs to innovative treatments.

Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.

Roman Fabbricatore

March 6th 2025

Durvalumab Combo Meaningfully Improves EFS in Advanced Gastric/GEJ Cancer

Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.

Related Content

Russ Conroy

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO

EC Approves Nivolumab/Ipilimumab in Frontline Unresectable HCC

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Tim Cortese

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

The CheckMate 9DW trial found that nivolumab and ipilimumab elicited a median OS of 23.7 months compared with 20.6 months from lenvatinib or sorafenib.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD

March 5th 2025

Celebrating Women in Oncology Through Their Impactful Research and Insights

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Ariana Pelosci